Xie Lingping, Du Tianhai, Wang Chao
Department of Pathology, Chengdu Shang Jin Nan Fu Hospital, Chengdu, China.
Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Discov Oncol. 2025 Jul 16;16(1):1340. doi: 10.1007/s12672-025-03107-9.
Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.
原发性乳腺鳞状细胞癌（PSCCB）是一种罕见的化生性乳腺癌（MpBC），约占所有浸润性乳腺癌的0.1%。它具有独特的形态学和临床特征，侵袭性高且预后较差。大多数分子亚型的雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER2）均为阴性，而HER2阳性的PSCCB更为罕见，约占病例的4-22%。准确的组织学诊断对有效治疗至关重要。目前，关于HER2阳性PSCCB的新辅助化疗联合靶向治疗的研究有限，尚未建立标准化的治疗方案。我们报告一例纯HER2阳性PSCCB病例，旨在积累HER2阳性PSCCB的治疗经验。
